Diana M Gibb
Gibb, Diana M.
VIAF ID: 310618350 (Personal)
Permalink: http://viaf.org/viaf/310618350
Preferred Forms
- 100 0 _ ‡a Diana M Gibb
- 100 1 _ ‡a Gibb, Diana M.
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Mortality risk over time after early fluid resuscitation in African children | |
Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission | |
National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links | |
The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries. | |
Nestlé's donation. | |
Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption | |
Neuroimaging young children and associations with neurocognitive development in a South African birth cohort study | |
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. | |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts | |
O123 To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS) | |
Opportunities for improving the efficiency of paediatric HIV treatment programmes | |
Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV | |
Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. | |
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. | |
Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life | |
Paediatric HIV infection--diagnostic and epidemiological aspects. | |
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe | |
Pediatric AIDS | |
Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda | |
PENTA guidelines for the use of antiretroviral therapy, 2004. | |
Perception of risk of vertically acquired HIV infection and acceptability of provider-initiated testing and counseling among adolescents in Zimbabwe | |
Performance of antenatal HIV screening strategies in the United Kingdom | |
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. | |
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children | |
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. | |
Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. | |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment | |
Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets | |
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults | |
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children | |
Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia | |
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children | |
Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection | |
Pneumocystis carinii pneumonia in vertically acquired HIV infection in the British Isles. | |
Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. | |
Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score | |
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study | |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial | |
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project | |
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. | |
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK | |
Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV? | |
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial | |
Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach | |
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis | |
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis. | |
Reduction of mother-to-child transmission of HIV infection: non-pharmaceutical interventions and their implementation. | |
Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. | |
Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child | |
Risk in the "Red Zone": outcomes for children admitted to Ebola holding units in Sierra Leone without Ebola virus disease | |
Risk of triple-class virological failure in children with HIV: a retrospective cohort study | |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial | |
Secondary re-analysis of the FEAST trial | |
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy | |
Sexual health of young people with perinatal HIV and HIV negative young people in England | |
She knows that she will not come back: tracing patients and new thresholds of collective surveillance in PMTCT Option B. | |
Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study | |
Short intensified treatment in children with drug-susceptible tuberculous meningitis | |
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. | |
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial | |
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years | |
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial | |
Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count? | |
Survival of HIV-1 vertically infected children | |
Sustainable and cost-effective monitoring of patients on ART. | |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? | |
Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial. | |
WHO decides what is fair?, May 2014: |